Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07545811 · ClinicalTrials.gov registry record · Phase 1
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Janux Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT07545811 is a Phase 1 study that is actively recruiting participants, run by Janux Therapeutics. The registered enrollment target is 43 participants.
The verdict
NCT07545811, a Phase 1 study, is actively recruiting participants, sponsored by Janux Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- BIOLOGICAL JANX014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07545811
The ClinicalTrials.gov registry entry for NCT07545811 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janux Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JANX014 is the first listed.
NCT07545811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07545811 about?
NCT07545811 is a clinical study titled "Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer". This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT07545811?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2026-04-15. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07545811?
The interventions under investigation include: JANX014 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07545811?
This trial is sponsored by Janux Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.